Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 1,365 INR
Change Today +60.60 / 4.65%
Volume 1.7M
ARBP On Other Exchanges
Symbol
Exchange
Natl India
OTC US
As of 6:22 AM 05/5/15 All times are local (Market data is delayed by at least 15 minutes).

aurobindo pharma ltd (ARBP) Snapshot

Open
1,299
Previous Close
1,304
Day High
1,369
Day Low
1,291
52 Week High
04/17/15 - 1,432
52 Week Low
05/12/14 - 576.00
Market Cap
398.5B
Average Volume 10 Days
1.5M
EPS TTM
40.27
Shares Outstanding
292.0M
EX-Date
02/16/15
P/E TM
33.9x
Dividend
2.00
Dividend Yield
0.39%
Current Stock Chart for AUROBINDO PHARMA LTD (ARBP)

Related News

No related news articles were found.

aurobindo pharma ltd (ARBP) Related Businessweek News

No Related Businessweek News Found

aurobindo pharma ltd (ARBP) Details

Aurobindo Pharma Limited, a pharmaceutical company, develops, manufactures, and markets generic pharmaceuticals and active pharmaceutical ingredients in India, the United States, Europe, and internationally. The company offers generics formulations primarily in the therapeutic areas of cardiovascular system, central nervous system, antibacterials, cephalosporins, opthalmics, oral contraceptives, gastroenterologicals, NSAIDS, anti-fungal, anti-emetics, anti-virals, anti-diabetics, anti-allergic, antibiotics, anti-retrovirals, and others. The company was founded in 1986 and is headquartered in Hyderabad, India.

9,500 Employees
Last Reported Date: 08/1/14
Founded in 1986

aurobindo pharma ltd (ARBP) Top Compensated Officers

Managing Director and Director
Total Annual Compensation: 15.9M
Whole Time Director, Member of Corporate Soci...
Total Annual Compensation: 9.0M
Vice Chairman, Chairman of Corporate Social R...
Total Annual Compensation: 9.0M
Whole Time Director and Member of Shareholder...
Total Annual Compensation: 9.0M
Compensation as of Fiscal Year 2014.

aurobindo pharma ltd (ARBP) Key Developments

Aurobindo Pharma Limited Presents at 4th Edition of Global Pharma Regulatory Summit 2015, Apr-24-2015 03:00 PM

Aurobindo Pharma Limited Presents at 4th Edition of Global Pharma Regulatory Summit 2015, Apr-24-2015 03:00 PM. Venue: The Lalit, Sahar Airport Road, Mumbai - 400059, Maharashtra. Speakers: Nagendra Irukulapati, Head Regulatory ­ Emerging Markets.

Aurobindo Pharma Ltd. Appoints Avnit Bimal Singh as Additional Non-Executive, Independent Director

Aurobindo Pharma Ltd. has informed that the Board of Directors of the company vide Circular Resolution dated  March 25, 2015 have appointed Dr. (Mrs.) Avnit Bimal Singh as an Additional Director (Non-Executive, Independent) of the company, effective March 25, 2015.

Aurobindo Pharma Limited Receives Final Approvals from the US Food & Drug Administration to Manufacture and Market Cefixime for Oral Suspension USP

Aurobindo Pharma Limited announced that the company has received final approvals from the US Food & Drug Administration (USFDA) to manufacture and market Cefixime for Oral Suspension USP, 100mg/5mL and 200mg/5mL (ANDA 204835). The product is ready for launch. The approved ANDA's are bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Suprax® Oral Suspension USP 100mg/5mL and 200mg/5mL respectively of Lupin Pharmaceuticals Inc. Cefixime for Oral Suspension is indicated for the treatment of adults and pediatric patients six months of age or older, with infections caused by susceptible strains of the designated organisms in urinary tract infections, otitis media, acute exacerbations of chronic bronchitis, uncomplicated gonorrhea (cervical/urethral), pharyngitis and tonsillitis The product has an estimated market size of $123 million for the twelve months ending February 2015. Aurobindo now has 11 ANDAs (represented by 7 product classes) approved out of Unit VI formulation facility in Hyderabad, India for manufacturing Oral Cephalosporin products.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ARBP:IN 1,364.90 INR +60.60

ARBP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Baxter International Inc $69.94 USD +0.51
Biocon Ltd 446.60 INR -7.30
Cipla Ltd/India 662.30 INR -11.40
Divi's Laboratories Ltd 1,749 INR -34.95
Shasun Pharmaceuticals Ltd 331.55 INR +5.60
View Industry Companies
 

Industry Analysis

ARBP

Industry Average

Valuation ARBP Industry Range
Price/Earnings 22.2x
Price/Sales 3.3x
Price/Book 8.1x
Price/Cash Flow 18.5x
TEV/Sales 3.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AUROBINDO PHARMA LTD, please visit www.aurobindo.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.